Trials / Completed
CompletedNCT02402621
Comparison Between Conventional and Model-based Infusion Strategy of IV PCA in Patients Undergoing RALP
Comparison Between Conventional and Model-based Infusion Strategy of Intravenous Patient-controlled Analgesia in Patients Undergoing Robot Assisted Laparoscopic Radical Prostatectomy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- Male
- Age
- 20 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
Comparing postoperative analgesics requirements and complications between conventional and model-based infusion strategy of intravenous patient-controlled analgesia in patients who undergoing robot assisted laparoscopic radical prostatectomy Group A: conventional intravenous patient-controlled analgesia, Group B: model-based infusion strategy of intravenous patient-controlled analgesia
Detailed description
The investigators compared postoperative analgesics requirements and complications between conventional and model-based infusion strategy of intravenous patient-controlled analgesia (IV PCA) in patients who undergoing robot assisted laparoscopic radical prostatectomy (RALP) Group A: conventional IV PCA, Group B: model based IV PCA 1. Primary endpoint: comparison of postoperative analgesic requirements in patient undergoing robot assisted laparoscopic radical prostatectomy (RALP) between conventional patient controlled analgesia (PCA) (Group A) and effective-compartment based dosing strategy of PCA (Group B) 2. Secondary endpoint: 1) VAS analysis between two groups, 2) postoperative nausea and vomiting analysis between two groups, 3) complication evaluation between two groups
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fentanyl | fentanyl with antiemetic drug |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2015-03-30
- Last updated
- 2015-12-02
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02402621. Inclusion in this directory is not an endorsement.